Does Tirzepatide Help You Live Longer? Mortality and Longevity Evidence

Does tirzepatide (Zepbound, Mounjaro) help you live longer? The honest answer is that we don't know yet. Unlike semaglutide, tirzepatide has no completed placebo-controlled trial of heart attacks, strokes and deaths in people with obesity, the kind of trial (SELECT) that showed semaglutide lowers deaths. That trial, SURMOUNT-MMO, has finished enrolling 15,374 participants, with primary completion expected in October 2027.^[9] In the meantime, a 2026 meta-analysis of 22 trials found 16% lower odds of death from any cause,^[2] and real-world data in people with diabetes and heart disease point the same way.^[7] Here is what the evidence shows, and what it doesn't.

The short answer

• A mortality signal, not yet a proven benefit. Across 22 trials (29,023 people), tirzepatide was associated with lower all-cause mortality (OR 0.84, 95% CI 0.75–0.93) and fewer major cardiovascular events (OR 0.87).^[2]
• Its big heart trial used an active comparator. In SURPASS-CVOT, tirzepatide was “noninferior” to dulaglutide, a GLP-1 drug already shown to lower heart events (HR 0.92), but not statistically superior.^[1]
• The definitive trial is still running. SURMOUNT-MMO is testing whether tirzepatide reduces illness and death in 15,374 adults with obesity; results are expected after October 2027.^[5][9]
• No aging-biomarker trials yet. We found no published randomized study of tirzepatide on epigenetic clocks or other measures of biological aging.

What the trials show

The meta-analysis. A 2026 review pooled 22 randomized trials. Tirzepatide was linked to fewer major cardiovascular events (rated high certainty) and lower all-cause mortality (the abstract gives no certainty rating for mortality). There was “a dose-response association,” with 2.8% lower odds of MACE for every 1 mg increase in dose, but “no association was observed for individual components of MACE or heart failure hospitalizations.”^[2] Most of the pooled trials were not designed to measure death, so this is a signal rather than a definitive answer.

SURPASS-CVOT. The large cardiovascular trial compared tirzepatide with dulaglutide in 13,165 people with type 2 diabetes and atherosclerotic heart disease. Heart attack, stroke or cardiovascular death occurred in 12.2% vs 13.1% (HR 0.92), which met the test for noninferiority (P = 0.003) but not superiority (P = 0.09).^[1] Because dulaglutide itself lowers cardiovascular events, the comparison sets a high bar. For more, see our SURPASS-CVOT review.

SUMMIT. In 731 people with obesity and heart failure with preserved ejection fraction, tirzepatide lowered the combined rate of cardiovascular death or worsening heart failure (9.9% vs 15.3%; HR 0.62), driven by fewer heart-failure events. Cardiovascular deaths were few and did not differ (8 vs 5; HR 1.58, 95% CI 0.52–4.83).^[3] See GLP-1s and heart failure.

Real-world data

A 2026 BMJ study used US insurance data on 52,971 adults aged 40 and over with type 2 diabetes and heart disease. It compared people starting tirzepatide with people starting sitagliptin, which was used as a stand-in for placebo because it doesn't affect cardiovascular outcomes. Over one year, tirzepatide was associated with a lower risk of major cardiovascular events (HR 0.68) and of all-cause death (HR 0.55), and with fewer serious infections.^[7] Observational studies can overstate benefits, though this one checked itself against negative control outcomes.

In 35,336 matched pairs of adults without diabetes, tirzepatide was associated with fewer cardiovascular events than semaglutide (HR 0.86), mostly less new heart failure, but “no significant differences were observed in all-cause mortality.”^[8]

Healthspan: diabetes prevention and older adults

Longevity is also about staying healthy for longer. In the three-year extension of SURMOUNT-1 in people with obesity and prediabetes, 1.3% of those on tirzepatide developed type 2 diabetes, compared with 13.3% on placebo (HR 0.07). After 17 weeks off treatment the figures were 2.4% vs 13.7%.^[6] In adults aged 65 and over, a pooled analysis of SURMOUNT and SUMMIT found weight loss and cardiometabolic benefits “broadly comparable” to younger adults, with no meaningful differences from placebo in falls, fractures or depression.^[4] For muscle concerns, see tirzepatide and lean mass.

What would settle the question

SURMOUNT-MMO is the “morbidity and mortality” trial for tirzepatide in obesity. It was designed to enroll about 15,000 participants aged 40 and over, with a BMI of 27 or more and either established cardiovascular disease or multiple cardiovascular risk factors, at 664 sites in 27 countries.^[5] ClinicalTrials.gov now lists 15,374 enrolled, recruitment closed, and primary completion expected in October 2027.^[9] Its results, together with any trials of aging biomarkers, will show whether tirzepatide matches the roughly 20% reduction in all-cause death that semaglutide showed in high-risk trials (see semaglutide and longevity).

Bottom line

Tirzepatide has a promising mortality signal from pooled trials and real-world data, strong evidence for preventing type 2 diabetes, and benefits in heart failure. But it does not yet have a completed SELECT-style placebo-controlled outcomes trial in obesity, and there is no human evidence that it slows biological aging. Anyone choosing it “for longevity” is ahead of the evidence. Anyone choosing it for obesity, diabetes or heart failure has good reasons already.